Oncolytics is developing pelareorep as a first-in-class double-stranded RNA immunotherapeutic with Fast Track Designation for colorectal and pancreatic cancer, as a platform immunotherapy for gastrointestinal tumors, supported by safety data from over 1,300 patients. Prior Phase 2 data (REO 022) showed median overall survival of 27 months and objective response rate of 33% versus approximately 11.2 months and 10% for standard therapy.
Cyborg Score Rationale
The company has achieved FDA Fast Track designation for colorectal and pancreatic cancer and is pursuing strategic partnerships to accelerate development and commercialization. Clinical data demonstrates substantial survival and response rate improvements over standard of care, with preliminary data from REO 033 expected by year-end 2026. However, as a clinical-stage company, regulatory and execution risks remain significant.
Top Insights
On March 2, 2026, Oncolytics announced the launch of REO 033, a randomized Phase 2 study in second-line metastatic colorectal cancer with preliminary data targeted by year-end 2026.
The company will prioritize registrational development of pelareorep in squamous cell anal cancer and metastatic colorectal cancer, planning an FDA meeting in mid-April for a single-arm anal cancer registrational study.
In first-line metastatic pancreatic cancer, pelareorep combination therapy achieved 45% one-year survival and 62% objective response rate, more than double historical control response rates.
In squamous anal cancer, 20 patients receiving pelareorep plus atezolizumab achieved 30% objective response rate, representing nearly 2.5x improvement over the 13.8% response rate for the only FDA-approved immunotherapy for this indication.
Named Competitors
Checkpoint Inhibitor Immunotherapy — Established PD-L1/PD-1 inhibitors dominating GI cancer treatment landscape
Talimogene Laherparepvec (T-VEC) — Oncolytic herpes simplex virus approved for melanoma; limited GI cancer data
Metastatic Pancreatic Cancer Chemotherapy — FOLFIRINOX and gemcitabine-based regimens with limited survival extension
Recent Developments
(March 2026) Launched REO 033 Phase 2 colorectal cancer trial with expected preliminary data by year-end 2026
(February 2026) Received FDA Fast Track Designation for second-line KRAS-mutant MSS metastatic colorectal cancer
(January 2026) Appointed senior executives (John McAdory as EVP Strategy and Operations; Yujun Wu as VP Head of Biostatistics) to support late-stage registration-directed development
(January 2026) Updated GOBLET Cohort 4 data in third-line squamous cell anal carcinoma showing 29% objective response rate
Open the full interactive Oncolytics Biotech Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.